NCT07133113 Medium-term Effects of Treatments in Autoimmune Encephalitis
| NCT ID | NCT07133113 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospices Civils de Lyon |
| Condition | NMDAR Autoimmune Encephalitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2024-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2024-09-01 with a primary completion date of 2024-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Autoimmune encephalitides are severe neurological disorders requiring urgent treatment, even though there is no standard guideline by lack of empirical evidence. Commonly used treatments are divided into so-called first-line (steroids, intravenous immunoglobulins, plasma exchanges) and second-line (rituximab, cyclophosphamide, tocilizumab, others), and may be used in association or sequentially. There is no standard practice, and initial treatment protocol may consist in first-line alone, first-line with rituximab, or first-line with dual immunosuppression (rituximab and cyclophosphamide). Absence of clear response to initial treatment in the first 4 to 6 weeks may indicate undertreatment and is generally followed by treatment escalation, mostly to dual immunosuppression. However, as the frequency of non-responders to initial treatment is unknown, it is still unclear whether dual immunosuppression should be offered to all patients from inception.
Eligibility Criteria
Inclusion Criteria: * Adult or child patient with encephalitis defined as anti-GAD, NMDAR, LGI1, CASPR2, IgLON5 or GFAP * Untreated or with a decision to treat within the previous 30 days. Exclusion Criteria: \- Refusal by the referring doctor to participate or refusal by the patient mentioned in the objection to the use of his/her clinical data.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07133113 clinical trial?
This trial is open to participants of all sexes, studying NMDAR Autoimmune Encephalitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07133113 currently recruiting?
Yes, NCT07133113 is actively recruiting participants. Contact the research team at bastien.joubert@chu-lyon.fr for enrollment information.
Where is the NCT07133113 trial being conducted?
This trial is being conducted at Bron, France.
Who is sponsoring the NCT07133113 clinical trial?
NCT07133113 is sponsored by Hospices Civils de Lyon. The trial plans to enroll 200 participants.